Global Drug Eluting Stents Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

This report extensively covers different segments of Global Drug Eluting Stents Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).

Global Drug Eluting Stents Segment Analysis

In this report, the Global Drug Eluting Stents Market has been segmented by Drug Coating, Application and Geography. Demand for coronary stents is expected to grow over the next few years due to the growing number of cardiovascular diseases (cvds) like stroke and heart attack, as well as the growing number of older people who are more likely to get these heart diseases. In fact, the company pretty much started the market for drug-eluting stents. But in about 5 years, it went from having more than 50% of the stent market to being just another player. Drug-eluting stents and the formation of clots or thrombosis later on: most stents made of bare metal or that don't have drugs on them are covered by body tissue within a few weeks. Once this happens, the stent is less likely to cause clots, and most people can stop taking plavix* about 2 months after the stent is put in place or deployed.

Global Drug Eluting Stents Market, Segmentation by Geography

In this report, the Global Drug Eluting Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Drug Eluting Stents Market Share (%), by Geographical Region, 2023

North America's dominance in the drug eluting stent (DES) is attributed to several factors. The region boasts a well-established healthcare infrastructure and a high adoption rate of advanced medical technologies, contributing to the widespread use of DES. Moreover, the rising prevalence of cardiovascular diseases in North America has fueled the demand for effective treatments like DES, further driving market growth. Key players in the market, coupled with ongoing advancements in stent technology, also play a significant role in maintaining North America's market dominance. For instance, Abbott's FDA approval for its XIENCE Skypoint stent in June 2021, featuring a unique polymer coating, exemplifies the region's commitment to innovative solutions and contributes to its leadership position.

Conversely, the Asia-Pacific region is poised to experience the fastest compound annual growth rate (CAGR) of 9.3% over the forecast period. This rapid growth can be attributed to several factors, including the increasing prevalence of cardiovascular diseases in the region and advancements in healthcare infrastructure, particularly in rural areas. Improved access to quality medical care has facilitated the adoption of DES in the Asia-Pacific region. For example, the launch of Terumo Corporation's Ultimaster Tansei Drug-Eluting Stent in Japan in September 2018 underscores the continuous progress and opportunities in the Asia-Pacific market for innovative stent technologies. As healthcare facilities continue to evolve and expand across the region, the demand for DES is expected to rise, driving market growth in the coming years.

This report provides an in depth analysis of various factors that impact the dynamics of Global Drug Eluting Stents Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunities

Drivers:

• Prevalence of Cardiovascular Diseases
• Technological Advancements in Stent Design

• Growing Adoption of Minimally Invasive Procedures: The shift towards minimally invasive procedures has significantly influenced the demand for drug-eluting stents (DES). Minimally invasive percutaneous coronary intervention (PCI) procedures, which utilize DES implantation, have emerged as preferred alternatives to traditional open-heart surgeries for treating coronary artery disease. These procedures offer numerous advantages, including lower procedural risks, shorter recovery times, and improved patient outcomes compared to invasive surgical interventions. As patients and clinicians alike recognize the benefits of minimally invasive approaches, the demand for DES as a primary therapy for coronary artery disease has continued to surge, propelling market expansion.

  The increasing adoption of minimally invasive techniques is driven by advancements in medical technology and techniques, which have enhanced the safety and efficacy of DES implantation procedures. Innovations in stent design, imaging technologies, and procedural techniques have contributed to improved patient outcomes and reduced complications associated with DES implantation. Consequently, the growing preference for minimally invasive procedures is expected to sustain the momentum in the DES market, driving further innovation and expansion in the coming years.

Restraints:

• Regulatory Hurdles
• Competition from Alternative Therapies

• Risk of Stent Thrombosis: Despite significant advancements in technology, the risk of stent thrombosis remains a persistent concern associated with Drug Eluting Stents (DES). Stent thrombosis occurs when a blood clot forms inside the stent, potentially leading to blockage of the coronary artery. While this complication is relatively rare, its consequences can be severe, including myocardial infarction (heart attack) or even death. This risk undermines the confidence of both physicians and patients in opting for DES as a treatment option for coronary artery disease.

  Physicians must carefully weigh the benefits of DES, such as reducing restenosis rates compared to bare-metal stents, against the potential risks of stent thrombosis. Factors such as patient's medical history, comorbidities, and lifestyle choices are crucial considerations in the decision-making process. Additionally, advancements in stent design, drug coatings, and antiplatelet therapy regimens aim to mitigate the risk of stent thrombosis. However, the possibility of this complication persists, leading some physicians and patients to explore alternative treatments or preventive measures. Continued research and development efforts are essential to further minimize the occurrence of stent thrombosis and enhance the safety profile of DES, thereby bolstering confidence in its use among healthcare providers and patients alike.

Opportunities:

• Emerging Markets
• Personalized Medicine

• Expansion into Adjacent Therapies: Expanding the application of drug-eluting stents (DES) beyond coronary artery disease presents a promising avenue for growth in the medical device industry. Peripheral artery disease (PAD), characterized by narrowed arteries in the limbs, is a significant health concern affecting millions worldwide. Traditional treatments for PAD, such as angioplasty and stenting, often face challenges with restenosis, where the treated artery becomes narrowed again. By applying DES technology to treat PAD, companies can potentially mitigate restenosis rates and improve long-term outcomes for patients. This expansion into the PAD market not only addresses an unmet medical need but also opens up a lucrative growth opportunity for DES manufacturers, particularly as the prevalence of PAD continues to rise globally.

  The exploration of DES applications in neurovascular interventions represents another avenue for expansion. Neurovascular diseases, including intracranial stenosis, pose serious risks such as stroke and cognitive impairment. While traditional treatment options like angioplasty and stenting exist, they often face challenges such as restenosis and thrombosis. By developing DES specifically tailored for neurovascular interventions, companies can potentially offer safer and more effective treatment options for patients. This diversification into neurovascular therapies not only expands the market reach of DES but also positions companies at the forefront of addressing critical neurological health issues. Overall, by exploring these adjacent therapies, companies can diversify their revenue streams, tap into new markets, and sustain long-term growth in the dynamic healthcare landscape.

Key players in Global Drug Eluting Stents Market include

• Abbott Laboratories
• Boston Scientific Corporation
• Terumo Corporation
• Medtronic
• Biosensors International
• Cook Medical
• Envision Scientific
• Biotronik
• Lepu Medical
• Stentsys

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis